Home Medizin AstraZeneca folgt dem Rivalen Boehringer bei der Begrenzung der Eigenkosten für Inhalatoren

AstraZeneca folgt dem Rivalen Boehringer bei der Begrenzung der Eigenkosten für Inhalatoren

von NFI Redaktion

(Reuters) – AstraZeneca, a pharmaceutical manufacturer, announced on Monday that it will limit the out-of-pocket costs for its inhalable respiratory products in the United States to $35 per month, following a similar move by its competitor, Boehringer Ingelheim, earlier this month.

High drug prices in the United States have been a subject of increasing political criticism for years. Senator Bernie Sanders and other lawmakers criticized the four largest inhaler manufacturers in the US – AstraZeneca, Boehringer, Teva Pharmaceuticals, and GlaxoSmithKline – for the high prices of their products in January.

In letters to these companies, lawmakers stated they would investigate what they consider „extremely high prices“ for asthma and chronic obstructive pulmonary disease inhalers in the US compared to other countries.

The cap by UK-based company AstraZeneca will apply to its entire respiratory product portfolio, including inhalers such as Airsupra, Bevespi Aerosphere, and Breztri Aerosphere, starting June 1 and will be applicable for uninsured or underinsured patients.

According to the lawmakers‘ letter, Breztri Aerosphere costs $645 in the US but only $49 in the UK.

„We remain committed to addressing the need for affordability of our medications, but the system is complex and we cannot do it alone,“ said Pascal Soriot, CEO of AstraZeneca. „It is crucial for Congress to bring key stakeholders together to help in reforming the healthcare system so that patients can afford the medications they need.“

Boehringer also announced that it will limit the out-of-pocket costs for its inhalation products for chronic lung diseases and asthma to $35 per month starting June 1.

The letter stated that Boehringer’s Combivent Respimat costs $489 in the US but only $7 in France.

Last year, Sanofi and Eli Lilly also announced plans to cap insulin prices at $35 per month.

(Reporting by Puyaan Singh in Bangalore; Editing by Shilpi Majumdar)

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.